MARCELO JUNQUEIRA ATANAZIO

(Fonte: Lattes)
Índice h a partir de 2011
1
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Autor e Coautores FMUSP-HC Normalizados: CARLOS ALBERTO BUCHPIGUEL ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • conferenceObject
    Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma
    (2022) SANTOS, Fernanda Maria Maria; MARIN, Jose Flavio Gomes; LIMA, Marcos Santos; SILVA, Wellington F.; VELASQUES, Rodrigo D.; MAIA, Ana Carolina Arrais; ATANAZIO, Marcelo Junqueira; ALVES, Lucas Bassolli de Oliveira; MOREIRA, Frederico Rafael; BUCHPIGUEL, Carlos Alberto; BUCCHERI, Valeria; ROCHA, Vanderson
  • article 0 Citação(ões) na Scopus
    Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma
    (2024) SANTOS, Fernanda Maria; MARIN, Jose Flavio Gomes; LIMA, Marcos Santos; SILVA-JUNIOR, Wellington Fernandes; ALVES, Lucas Bassolli O.; MOREIRA, Frederico R.; VELASQUES, Rodrigo Dolphini; ATANAZIO, Marcelo Junqueira; MAIA, Ana Carolina Arrais; BUCHPIGUEL, Carlos A.; BUCCHERI, Valeria; ROCHA, Vanderson
    Currently, analysis of interim PET (iPET) according to the Deauville score (DS) is the most important predictive factor in Hodgkin lymphoma (HL); however, there is room for improvement in its prognostic power. This study aimed to evaluate the prognostic value of quantitative PET analysis (maximum standard uptake value [SUVmax], total metabolic tumor volume [TMTV] and total lesion glicolysis [TLG]) at baseline (PET0) and iPET in a retrospective cohort of newly diagnosed classical HL. For positive iPET (+ iPET), the reduction of quantitative parameters in relation to PET0 (Delta SUVmax, Delta TMTV and Delta TLG) was calculated. Between 2011 and 2017, 234 patients treated with ABVD were analyzed. Median age was 30 years-old, 59% had advanced stage disease, 57% a bulky mass and 25% a + iPET (DS 4-5). At baseline, high TLG was associated with an increased cumulative incidence of failure (CIF) (p = 0.032) while neither SUVmax, TMTV or TLG were associated with overall survival (OS) or progression-free survival (PFS). In multivariate analysis, only iPET was associated with CIF (p < 0.001). Among Delta SUVmax, Delta TMTV and Delta TLG, only a Delta SUVmax >= 68.8 was significant for PFS (HR: 0.31, CI95%: 0.11-0.86, p = 0.024). A subset of patients with improved PFS amongst + iPET was identified by the quantitative (Delta SUVmax >= 68.8%) analysis. In this real-world Brazilian cohort, with prevalent high-risk patients, quantitative analysis of PET0 did not demonstrate to be prognostic, while a dynamic approach incorporating the Delta SUV(max )to + iPET succeeded in refining a subset with better prognosis. These findings warrant validation in larger series and indicate that not all patients with + iPET might need treatment intensification.